Member Info for Shukan

One last sentence : from Hemogenyx “proof of principle in huminised mice” - now your filtered

I refere you to Fridays posts where it’s in black and white proof of principle humanised mice - research and you will find my buy in price and how many I hold , it’s all posted here , I will say certainly not sitting on a loss far from it , compared to you , In fact while playing silly buggers with you I was buying at 4.47p again what’s your holding a big fat 0 Now I cant stop laughing again, remind me of the sp as of now

So Domestos Dave who are you on Twitter ? Bet I have you blocked on there along with the other numpties that don’t know S**T in reference to Hemogenyx

I am a stem cell biologist. I trained with the generation of humanized animal models. Big fan of Hemogenyx work. They are the new frontier. I don't work for them. In response to me a quick google finds him

every posts shows a tendency for attention seeking, there is a word for it within the mental health act a classic case here- when your knowledge extends to bleach and bonfires in vitro you do think that the block button is relevant in this case . It’s a shame as it detracts from the work that Hemogenyx is doing for the good of man this imbecile rubbishing the discussion with Simpleton words.

Two recent tweets by Hemogenyx refer to CTC,s circulating Tumour Cells within the blood - exciting times ahead

DD - its been a laugh to-day , see you at 10p have a good weekend

change of tact - carry on

yes Toilet material

smoking something - or he really believes the rubbish he post - carry on I have not stopped laughing yet

Hello Domestos Dave is back with more technical insite on bleach - but hang on we are now into bonfires in vitro dishes - comedy gold right here

DA - tone it down HEMO does not need u rampant here it’s own newsflow will dictate - with respect

Nothing - except a big deal on what?

LOL- DD love to know what plank is ticking u up though

Dr. Vladislav Sandler joined Weill Cornell Medical College in 2011, where he identified a new source of cells (Hu-PHEC) inside adult blood vessels that can be used for generation of HSC. This was based on the observation that HSC arise from embryonic hemogenic endothelial cells, which can also be found in adults (postnatal). Previously, it was believed that these cells only existed during embryonic development. Dr. Sandler also discovered and showed that it is possible to isolate the Hu-PHEC and restore their hematopoietic potential. In 2013, Dr. Sandler co-founded Hemogenyx LLC together with Alexis M. Sandler. In 2014, Dr. Sandler received the Daedalus Award for Innovation, a grant awarded to him specifically to pursue the Hu-PHEC cell-related research and treatments that Hemogenyx LLC is undertaking. Cornell University applied for patent protection for the method of Hu-PHEC isolation and their use for hematopoietic system regeneration, which was granted in early 2015 and achieved proof of principle in using the Hu-PHEC for hematopoietic system regeneration. Dr. Sandler realised that a successful BM/HSC transplant depended not only on the quality of the transplanted cells, but also on the method used to condition patients for a transplant. This realisation led him to develop a new type of conditioning, known as the CDX bi-specific antibodies. These antibodies function by binding to the unwanted cells and immune T cells, which then target to eliminate the unwanted cells. The CDX bi-specific antibodies will potentially provide a more selective and safe approach to conditioning.

while we wait for DD, The current method for BM/HSC transplantations comprises of two phases. The initial phase (�conditioning�) involves patients receiving high dosages of chemotherapy to eliminate cancerous cells and destroys the HSC in the BM, but it is highly toxic for patients. The second phase involves transplanting cells from a healthy individual into the patient, which has a high rejection rate and issues with finding a tissue matched donor. In this procedure, the non-toxic CDX antibodies redirect the patient�s immune cells to selectively eliminate the HSC and in some instances the cancerous cells, thereby avoiding the need for toxic conditioning agents. Additionally, Hemogenyx has identified a special class of cells, Hu-PHECs, derived from the umbilical cord or the liver endothelia. Hu-PHECs are a naturally occurring cell type, which can be easily isolated and they do not accumulate blood cancer-related mutations. Above all, HuPHECs can potentially eliminate the problem of having to find tissue matched donors when isolated from the patient�s own liver.

where is it mentioned proof of principle in a dish?

I will tell you -HUMINISED MICE -his argument being dismantled post by post

So Dave how have they established proof of principle?

Hemogenyx has established proof-of-principle for its two complementary technologies; CDX bi-specific antibodies and Human Postnatal Hemogenic Endothelial Cells (�Hu-PHECs�), both of which aim to address the limitations and dangers of the current method for a bone marrow (�BM�) or hematopoietic (blood) stem cell (�HSC�) transplant.